| Literature DB >> 24742308 |
Sara R Jacobs1, Bryan J Weiner, Alicia C Bunger.
Abstract
BACKGROUND: It has been noted that implementation climate is positively associated with implementation effectiveness. However, issues surrounding the measurement of implementation climate, or the extent to which organizational members perceive that innovation use is expected, supported and rewarded by their organization remain. Specifically, it is unclear whether implementation climate can be measured as a global construct, whether individual or group-referenced items should be used, and whether implementation climate can be assessed at the group or organizational level.Entities:
Mesh:
Year: 2014 PMID: 24742308 PMCID: PMC4012549 DOI: 10.1186/1748-5908-9-46
Source DB: PubMed Journal: Implement Sci ISSN: 1748-5908 Impact factor: 7.327
Exploratory factor analysis results
| | | | | | |||
|---|---|---|---|---|---|---|---|
| Q1 | I am expected to enroll a certain number of patients in NCI clinical trials. | 47 | 3.37 | 1.05 | -0.04 | 0.01 | -0.01 |
| Q2 | I am expected to help the CCOP meet its clinical trial enroll. | 47 | 4.20 | 1.09 | 0.02 | 0.04 | 0.70 |
| Q3 | I get research support to identify potentially eligible patients for NCI clinical trials. | 47 | 3.79 | 1.25 | -0.01 | 0.93 | 0.03 |
| Q4 | I get research support to enroll patients in NCI clinical trials. | 47 | 4.08 | 1.17 | 0.05 | 0.95 | -0.05 |
| Q5 | I receive recognition when I enroll patients in NCI clinical trials. | 47 | 3.17 | 1.31 | 0.98 | 0.02 | -0.01 |
| Q6 | I receive appreciation when I enroll patients in NCI clinical trials. | 47 | 3.27 | 1.28 | 0.70 | 0.04 | -0.01 |
| Q7 | Physicians are expected to enroll a certain number of patients in NCI clinical trials. | 47 | 3.46 | 1.35 | 0.04 | -0.01 | 0.02 |
| Q8 | Physicians are expected to help the CCOP meet its clinical trial enroll. | 47 | 4.18 | 0.98 | 0.03 | -0.03 | 0.70 |
| Q9 | Physicians get support to identify potentially eligible patients for NCI clinical trials. | 47 | 3.81 | 1.08 | 0.04 | 0.77 | -0.03 |
| Q10 | Physicians get support to enroll patients in NCI clinical trials. | 47 | 3.96 | 1.08 | 0.05 | 0.80 | 0.05 |
| Q11 | Physicians receive recognition when I enroll patients in NCI clinical trials. | 47 | 3.27 | 1.23 | 0.96 | 0.03 | 0.02 |
| Q12 | Physicians receive appreciation when I enroll patients in NCI clinical trials. | 47 | 3.37 | 1.19 | 0.69 | 0.06 | 0.01 |
| Q1 | I am expected to use TF-CBT with a certain number of clients. | 26 | 3.74 | 0.83 | 0.07 | -0.05 | 0.28 |
| Q2 | I am expected to help my agency meet its goals for implementing TF-CBT. | 26 | 4.32 | 0.63 | -0.01 | 0.03 | 0.88 |
| Q3 | I get the support I need to identify potentially eligible clients for TF-CBT. | 26 | 4.20 | 0.89 | 0.92 | 0.09 | 0.14 |
| Q4 | I get the support I need to use TF-CBT with my clients. | 26 | 4.14 | 0.87 | 0.89 | -0.02 | -0.12 |
| Q5 | I receive recognition when I use TF-CBT with my clients. | 26 | 3.38 | 0.73 | 0.20 | 0.42 | 0.08 |
| Q6 | I receive appreciation when I use TF-CBT with my clients. | 26 | 3.19 | 0.81 | 0.14 | 0.79 | -0.07 |
| Q7 | Clinicians are expected to use TF-CBT with a certain number of clients. | 26 | 3.68 | 0.89 | -0.07 | 0.15 | 0.40 |
| Q8 | Clinicians are expected to help our agency meet its goals for implementing TF-CBT. | 26 | 4.15 | 0.55 | 0.11 | 0.01 | 0.82 |
| Q9 | Clinicians get the support they need to identify potentially eligible clients for TF-CBT. | 26 | 4.06 | 0.87 | 0.38 | -0.07 | 0.23 |
| Q10 | Clinicians get the support they need to use TF-CBT with eligible clients. | 26 | 3.92 | 1.07 | 0.05 | 0.12 | -0.13 |
| Q11 | Clinicians receive recognition for using TF-CBT with eligible clients. | 26 | 3.39 | 0.81 | 0.03 | 0.76 | 0.06 |
| Q12 | Clinicians receive appreciation for using TF-CBT with eligible clients. | 26 | 3.25 | 0.92 | -0.20 | 1.01 | 0.05 |
Figure 1Five-step process to determine group-level construct from individual data.
Figure 2Example of second order CFA model for individually referenced items.
Figure 3Example of second order CFA model for group-referenced items.
Confirmatory factor analysis results
| Individual referenced items: observed variables | ||
| Q1 | 0.563 (0.061) | 0.821 (0.081) |
| Q2 | 0.948 (0.087) | 0.597 (0.078) |
| Q3 | 0.894 (0.029) | 0.851 (0.040) |
| Q4 | 0.853 (0.029) | 0.953 (0.036) |
| Q5 | 0.9050 (.029) | 0.932 (0.031) |
| Q6 | 0.862 (0.029) | 0.895 (0.033) |
| Individual referenced items: latent variables | ||
| Expectations | 0.457 (0.067) | 0.717 (0.089) |
| Support | 0.743 (0.067) | 0.757 (0.071) |
| Rewards | 0.695 (0.063) | 0.859 (0.068) |
| Group referenced items: observed variables | ||
| Q7 | 0.597 (0.060) | 0.860 (0.052) |
| Q8 | 0.854 (0.075) | 0.941 (0.052) |
| Q9 | 0.845 (0.028) | 0.808 (0.059) |
| Q10 | 0.900 (0.028) | 0.943 (0.061) |
| Q11 | 0.922 (0.025) | 0.916 (0.035) |
| Q12 | 0.850 (0.026) | 0.946 (0.034) |
| Group referenced items: latent variables | ||
| Expectations | 0.458 (0.063) | 0.637 (0.097) |
| Support | 0.664 (0.063) | 0.688 (0.103) |
| Rewards | 0.836 (0.071) | 0.736 (0.098) |
Standard Error in parenthesis.
Study 1 Individual Referenced: X2 = 0.2391 CFI = 0.998; TLI = 0.996; SRMR = 0.015; RMSEA = 0.027.
Study 1 Group Referenced: X2 = 0.1146 CFI = 0.997; TLI = 0.990; SRMR = 0.013 RMSEA = 0.040.
Study 2 Individual Referenced: X2 = 0.6650 CFI = 1.00; TLI = 1.01; SRMR = 0.012; RMSEA = 0.00.
Study 2 Group Referenced: X2 = 0.629 CFI = 0.996; TLI = 0.983; SRMR = 0.013; RMSEA = 0.065.
Correlations between items and scales within and between groups
| Q1 x Q7 | 0.78 | 0.53 | 0.73 | 0.43 | 0.92 | 0.68 |
| Q2 x Q8 | 0.76 | 0.71 | 0.75 | 0.65 | 0.86 | 0.84 |
| Q3 x Q9 | 0.75 | 0.59 | 0.74 | 0.31 | 0.80 | 0.83 |
| Q4 x Q10 | 0.75 | 0.55 | 0.74 | 0.40 | 0.84 | 0.64 |
| Q5 x Q11 | 0.81 | 0.78 | 0.79 | 0.76 | 0.92 | 0.74 |
| Q6 x Q12 | 0.78 | 0.76 | 0.78 | 0.72 | 0.78 | 0.82 |
| Scale average | 0.83 | 0.66 | 0.82 | 0.51 | 0.89 | 0.83 |
| Percentage of shared variance | 69% | 44% | 67% | 26% | 79% | 69% |
Study 1: N and N = 470; N = 47.
Study 2: N and N = 135; N = 26.
All correlations significant at p < .01.
ICC(1), ICC(2), and WABA I results
| | | | | ||||
|---|---|---|---|---|---|---|---|
| Study 1: Individual referenced | 0.07 | 0.44 | 1.80** | 0.40 | 0.91 | 0.44 | 0.55 |
| Study 1: Group referenced | 0.08 | 0.48 | 2.14** | 0.43 | 0.90 | 0.48 | 0.47 |
| Study 2: Individual referenced | 0.29 | 0.66 | 2.92 ** | 0.65 | 0.76 | 0.86 | 0.21 |
| Study 2: Group referenced | 0.33 | 0.70 | 3.37** | 0.67 | 0.74 | 0.91 | 0.19 |
Note: ICC = intraclass correlation coefficient; WABA = within and between analysis **p < .01.
aStudy 1: df(within) = 423 for individual referenced = 426 for group referenced; df(between) = 46.
bStudy 2: df(within) = 133 for individual referenced =129 for group referenced; df(between) = 26.
cE-test for parts significant at 30°.
dA parts condition, in which ηw > ηb requires an inverse F-test (1/F) with df = N – J and J – 1 for the numerator and denominator respectively.
Interrater agreement
| Study 1 | 47 | 0.74 | 89% | 0.79 | 94% |
| Study 2 | 26 | 0.73 | 58% | 0.76 | 62% |
Factor analysis within groups
| % Variance | 80% | 91% | 82% | 66% | 29% |
| Component loadings | | | | | |
| Q1 | 0.36 | 0.38 | | | |
| Q2 | 0.46 | 0.25 | | | |
| Q3 | 0.71 | 0.26 | | | |
| Q4 | 0.69 | 0.39 | | | |
| Q5 | 0.74 | 0.80 | | | |
| Q6 | 0.72 | 0.80 | | | |
| Q7 | | | 0.31 | 0.15 | 0.84 |
| Q8 | | | 0.41 | 0.20 | 0.83 |
| Q9 | | | 0.69 | 0.16 | 0.14 |
| Q10 | | | 0.70 | 0.29 | 0.00 |
| Q11 | | | 0.77 | 0.86 | 0.14 |
| Q12 | 0.75 | 0.87 | 0.20 | ||